Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. JSPR
stocks logo

JSPR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.668
-58.75%
--
--
-0.723
-48.7%
--
--
-0.740
-57.47%
Estimates Revision
The market is revising No Change the revenue expectations for Jasper Therapeutics, Inc. (JSPR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -31.62%.
EPS Estimates for FY2025
Revise Downward
down Image
-17.53%
In Past 3 Month
Stock Price
Go Down
down Image
-31.62%
In Past 3 Month
Wall Street analysts forecast JSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JSPR is 9.25 USD with a low forecast of 4.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast JSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JSPR is 9.25 USD with a low forecast of 4.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.860
sliders
Low
4.00
Averages
9.25
High
20.00
Current: 1.860
sliders
Low
4.00
Averages
9.25
High
20.00
Citizens JMP
Outperform
to
NULL
downgrade
$12 -> $6
2025-09-22
Reason
Citizens JMP
Price Target
$12 -> $6
2025-09-22
downgrade
Outperform
to
NULL
Reason
Citizens JMP lowered the firm's price target on Jasper Therapeutics to $6 from $12 and keeps an Outperform rating on the shares. Jasper Therapeutics announced early findings from its investigation into the confounding results from two cohorts in the BEACON study, and the issue now points to sites or enrolled patients, the analyst says. Jasper also announced the pricing of a $30M public offering, which will extend its runway past updated CSU data coming at year-end 2025 and into the third quarter of 2026. The bridge financing deal removes a key overhang for Jasper, Citizens says.
UBS
Buy
downgrade
$29 -> $25
2025-08-15
Reason
UBS
Price Target
$29 -> $25
2025-08-15
downgrade
Buy
Reason
UBS lowered the firm's price target on Jasper Therapeutics to $25 from $29 and keeps a Buy rating on the shares. Jasper's Q2 print was "straightforward," while the focus turns to the critical BEACON data in Q4, the analyst tells investors in a research note.
RBC Capital
Outperform -> Sector Perform
downgrade
$46 -> $5
2025-07-08
Reason
RBC Capital
Price Target
$46 -> $5
2025-07-08
downgrade
Outperform -> Sector Perform
Reason
RBC Capital downgraded Jasper Therapeutics to Sector Perform from Outperform with a price target of $5, down from $46.
Citizens JMP
Outperform
to
NULL
downgrade
$70 -> $12
2025-07-08
Reason
Citizens JMP
Price Target
$70 -> $12
2025-07-08
downgrade
Outperform
to
NULL
Reason
Citizens JMP lowered the firm's price target on Jasper Therapeutics to $12 from $70 and keeps an Outperform rating on the shares after the company disclosed updates for the Phase 1b/2a BEACON study of briquilimab for chronic spontaneous urticaria. The CSU readout fell flat due to a likely manufacturing issue and the company will try again in 4Q25, which further increases pressure from a financing overhang, the analyst tells investors in a research note. Based on new data from the interim update from the single dose and early look at the open-label extension, the firm continues to have confidence in our view that briquilimab can be differentiated on a dosing schedule and risk/benefit profile.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$40 -> $20
2025-07-07
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$40 -> $20
2025-07-07
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Jasper Therapeutics to $20 from $40 and keeps a Buy rating on the shares after the company's "surprising update" that the 240 mg every 8 week and 240 mg loading dose plus 180 mg every 8 week cohorts in the BEACON trial evaluating briquilimab for treatment of chronic spontaneous urticaria were impacted by issues with one drug product lot. The firm updated its model to shift its launch estimates for CSU and chronic inducible urticaria in the U.S. to 2030 and 2031, respectively, and to account for the company's cost-cutting plans and lower operating expenses in 2025. However, the firm still believes the company will need to raise capital and currently estimates a $5M raise.
William Blair
William Blair
Outperform -> Market Perform
downgrade
2025-07-07
Reason
William Blair
William Blair
Price Target
2025-07-07
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded Jasper Therapeutics to Market Perform from Outperform after the company reported updated data from the BEACON study and preliminary data from the open-label extension of briquilimab in chronic spontaneous urticaria. Jasper also disclosed that some of the multi-dose cohorts from BEACON were impacted by an inactive drug product lot and that development of briquilimab in asthma has been halted because the same inactive drug product lot was used for all patients in the ETESIAN asthma challenge study, the analyst noted. The firm is downgrading shares as a result of this "setback," citing a lack of clarity around both the funding overhang and concerns related to drug product manufacturing.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Jasper Therapeutics Inc (JSPR.O) is -0.55, compared to its 5-year average forward P/E of -3.72. For a more detailed relative valuation and DCF analysis to assess Jasper Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.72
Current PE
-0.55
Overvalued PE
-0.47
Undervalued PE
-6.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.56
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.67
Undervalued EV/EBITDA
-4.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.56
Current PS
0.00
Overvalued PS
3.54
Undervalued PS
-2.41
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 364.54% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

JSPR News & Events

Events Timeline

(ET)
2025-12-02
07:10:00
Jasper Therapeutics Reports Positive Phase 1b Results for Briquilimab in Allergic Asthma
select
2025-11-10 (ET)
2025-11-10
08:04:16
Jasper Therapeutics announces Q3 EPS of $1.13, below consensus estimate of $1.29
select
2025-09-19 (ET)
2025-09-19
05:59:19
Jasper Therapeutics Prices 11.67M Share Spot Secondary at $2.43
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Benzinga
PinnedJasper Stock Soars Following Positive Results from New Asthma Study

  • Briquilimab Study Results: Jasper Therapeutics released preliminary data from the ETESIAN Phase 1b study showing that a single 180mg dose of briquilimab significantly reduced sputum eosinophils and improved lung function indicators in adults with allergic asthma, demonstrating a favorable safety profile.

  • Eosinophil Reduction: Treatment with briquilimab led to substantial decreases in sputum eosinophil levels before and after allergen challenges, indicating its potential effectiveness in managing allergic asthma symptoms.

  • BEACON Cohort Investigation: Jasper completed an internal investigation into the lack of clinical response in the BEACON study cohorts, concluding that the unexpected results were likely due to patient selection issues rather than problems with the drug itself.

  • Stock Performance: Following the positive study results, Jasper Therapeutics' shares increased by 8.72%, reaching $1.87 at the time of publication.

[object Object]
Preview
9.0
12-02NASDAQ.COM
PinnedJasper Therapeutics Announces Encouraging Findings for Briquilimab in Phase 1b Study of Allergic Asthma

  • Study Overview: Jasper Therapeutics reported positive preliminary data from its ETESIAN Phase 1b study of briquilimab for allergic asthma, showing significant reductions in sputum eosinophils and improvements in lung function.

  • Efficacy Results: A single dose of briquilimab resulted in notable improvements in FEV1 during both Early and Late Asthmatic Responses, along with significant reductions in serum tryptase levels.

  • Safety Profile: The treatment was well tolerated, indicating a favorable safety profile for briquilimab in the study participants.

  • Future Development: The encouraging results support the ongoing development of briquilimab as a potential new treatment option for asthma.

[object Object]
Preview
9.0
12-02Globenewswire
Jasper Reports Positive ETESIAN Study Data for Briquilimab, 180mg Dose Shows Significant Asthma Improvement
  • Positive Clinical Data: The ETESIAN study revealed that a single 180mg dose of briquilimab significantly reduced airway hyperresponsiveness and eosinophil levels at both 6 and 12 weeks, indicating its potential in asthma treatment.
  • Favorable Safety Profile: Briquilimab demonstrated good tolerability in the study, with no dose-limiting toxicities observed, enhancing its appeal as a new therapeutic option.
  • Resolution of Patient Selection Issues: Jasper concluded its internal investigation into the lack of clinical response in the BEACON study, confirming that the issue stemmed from patient selection rather than drug product, ensuring the validity of future studies.
  • Promising Future Development: Jasper plans to initiate a Phase 2b study for chronic spontaneous urticaria in mid-2026, leveraging the positive outcomes from the ETESIAN study to further advance briquilimab's development.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Jasper Therapeutics Inc (JSPR) stock price today?

The current price of JSPR is 1.86 USD — it has increased 12.73 % in the last trading day.

arrow icon

What is Jasper Therapeutics Inc (JSPR)'s business?

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

arrow icon

What is the price predicton of JSPR Stock?

Wall Street analysts forecast JSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JSPR is 9.25 USD with a low forecast of 4.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Jasper Therapeutics Inc (JSPR)'s revenue for the last quarter?

Jasper Therapeutics Inc revenue for the last quarter amounts to -19.17M USD, decreased -3.64 % YoY.

arrow icon

What is Jasper Therapeutics Inc (JSPR)'s earnings per share (EPS) for the last quarter?

Jasper Therapeutics Inc. EPS for the last quarter amounts to -16999000.00 USD, increased 18.66 % YoY.

arrow icon

What changes have occurred in the market's expectations for Jasper Therapeutics Inc (JSPR)'s fundamentals?

The market is revising No Change the revenue expectations for Jasper Therapeutics, Inc. (JSPR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -31.62%.
arrow icon

How many employees does Jasper Therapeutics Inc (JSPR). have?

Jasper Therapeutics Inc (JSPR) has 64 emplpoyees as of December 05 2025.

arrow icon

What is Jasper Therapeutics Inc (JSPR) market cap?

Today JSPR has the market capitalization of 51.77M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free